曲安奈德注射治疗成人烧伤增生性瘢痕的随机对照试验
Intralesional corticosteroid (triamcinolone acetonide [TAC]) injections have become one of the cornerstone treatments of hypertrophic scar (HSc).…
要点
- TAC注射可显著降低烧伤增生性瘢痕厚度并增加弹性
- TAC对瘢痕红斑和黑色素无显著改善作用
- 末次注射后6周随访期内瘢痕特征无显著变化
核心结论
- TAC注射治疗成人烧伤增生性瘢痕较常规护理显著降低厚度并增加弹性,但对红斑和黑色素无显著影响。
研究设计与样本
- 入选标准包括高频超声厚度>2.034 mm且两部位预处理厚度差在0.5 mm以内、红斑指数>300。
- 30例完成研究,达到基于预试验数据分析的足够把握度样本量。
主要发现
- 配对t检验显示TAC注射瘢痕和对照瘢痕厚度均显著降低,TAC注射瘢痕弹性增加,对照瘢痕弹性无显著变化。
- 重复测量回归模型控制预处理值和皮肤类型后,6周随访期内厚度、弹性、红斑或黑色素均无显著变化。
关键数值与推荐
- TAC注射浓度为10 mg/ml,必要时6周后重复注射,再6周后第三次注射。
- 10例仅接受1次注射,27例接受2次注射,13例接受3次注射。
- 高频超声厚度>2.034 mm且两部位预处理厚度差≤0.5 mm,红斑指数>300。
临床怎么用
- 对于成人烧伤增生性瘢痕,可考虑病灶内注射10 mg/ml TAC以降低厚度并增加弹性。
- TAC注射对瘢痕红斑和色素沉着无明显改善,需结合其他治疗手段。
- 注射后6周内瘢痕特征稳定,可按6周间隔重复注射。
局限性
- 单盲设计,仅评估者盲法。
- 随访期仅末次注射后6周,长期疗效未知。
- 未报告不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intralesional corticosteroid (triamcinolone acetonide [TAC]) injections have become one of the cornerstone treatments of hypertrophic scar (HSc). However, the evidence is of limited-quality, and published investigations have almost exclusively been performed in linear scars rather than hypertrophic burn scars. Thus, the aim of this study was to perform an appropriately powered, single-blinded, randomized controlled trial to evaluate the impact of TAC injections on burn HSc compared with patient-matched usual care control scars. Fifty burn survivors with two scars (separated by nonscarred skin preferably on the contralateral side or an anatomically similar site) were selected based on high-frequency ultrasound thickness (>2.034 mm to ensure that the site was outside of the range of normal scar). Pretreatment thickness measurements of the two sites were within 0.5 mm of each other, to ensure homogeneity and an erythema index >300 to establish they were immature HSc. The sites were randomly assigned to treatment or control. The treatment HSc received a 10 mg/ml TAC. When necessary, the injection was repeated after 6 weeks and a third final injection 6 weeks later. Objective evaluation of thickness, elasticity, erythema, and melanin was obtained at the treatment and control sites at pretreatment, posttreatment, and follow-up 6 weeks after the last injection. Thirty participants completed the study, reaching the required number for an adequately powered sample based on pilot study data analyses. Ten participants received only one injection, 27 received only two injections, and 13 received three injections of TAC. Analysis of covariance comparing the treatment vs control HSc posttreatment, controlling for pretreatment values and Fitzpatrick skin type, revealed a significant decrease in thickness and increase in elasticity of the treated compared with control HSc (P = .0003), but no significant difference in erythema or melanin. Pretreatment to posttreatment comparisons using paired t-tests revealed a significant decrease in thickness of both the treated and control HSc, an increase in elasticity of the treated HSc during the treatment period, but no significant change in the control HSc elasticity or erythema of either site, and a significant increase in melanin of both the treated (P < .001) and control (P = .02) HSc. A regression model for repeated measures, controlling for pretreatment values and skin type, revealed no significant change in thickness, elasticity, erythema, or melanin during the 6-week follow-up. Although thickness decreased at both the treated and control HSc across time, there was a significantly greater reduction at the TAC injected HSc and a significantly greater increase in elasticity. Melanin significantly increased at both the treatment and control site. There was no significant change during the follow-up period of any of the HSc characteristics.
引用
- Nedelec B, LaSalle L, de Oliveira A, et al. Within-Patient, Single-Blinded, Randomized Controlled Clinical Trial to Evaluate the Efficacy of Triamcinolone Acetonide Injections for the Treatment of Hypertrophic Scar in Adult Burn Survivors. J Burn Care Res. 2020. PMID: 32303737. doi:10.1093/jbcr/iraa057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。